Heranova Lifesciences has secured nearly $10 million in seed funding to spearhead innovative women's health solutions, particularly focusing on non-invasive diagnostics for endometriosis and other gynecological treatments in the Asia-Pacific region.

Target Information

Heranova Lifesciences Holding, commonly known as 合凯维, has successfully completed nearly $10 million in seed funding as of March 8, 2023, in Boston, Massachusetts, and Hong Kong, China. The company is dedicated to advancing innovative solutions in global women's health, focusing on the development and commercialization of groundbreaking products. This funding will primarily be utilized to accelerate the commercialization efforts of the company's pioneering, non-invasive molecular diagnostics for endometriosis, as well as innovative prenatal and gynecological treatment products in the Asia-Pacific region.

Heranova is also actively engaged in the early development of innovative drugs targeting endometriosis and gynecological inflammation, collaborating with global partners to expand solutions for critical gynecological indications. The seed round was co-led by鼎丰生科资本 and 创新工场.

Industry Overview in Target’s Specific Country

The women's health sector in China is experiencing significant growth, driven by an increasing awareness of women's health issues and a rising demand for innovative healthcare solutions. Despite representing a vita